Market research
CP1.AU CannPal Animal Therapeutics Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 16M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 1.05
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- AU000000CP17
- Market cap
- 16M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 1.05
About
About CannPal Animal Therapeutics Limited
CannPal Animal Therapeutics Limited, an animal health company, engages in the research and development of plant-based therapeutic products for pets in Australia. It develops CPAT-01, a cannabis-derived pharmaceutical product to provide veterinarians and pet owners to treat pain and inflammation in dogs. The company was incorporated in 2016 and is based in Double Bay, Australia. As of March 11, 2021, CannPal Animal Therapeutics Limited operates as a subsidiary of AusCann Group Holdings Ltd.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CP1.AU discussion.
5 years, 5 months ago
CannPal Animal Therapeutics Limited is currently in a long term uptrend where the price is trading 16.6% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
CannPal Animal Therapeutics Limited's total revenue rose by 8.5% to $756K since the same quarter in the previous year.
Its net income has increased by 46.8% to $-273K since the same quarter in the previous year.
Finally, its free cash flow grew by 43.0% to $-252K since the same quarter in the previous year.
Based on the above factors, CannPal Animal Therapeutics Limited gets an overall score of 5/5.